Association of variants in the ABCB1, CYP2C19 and CYP2C9 genes for Juvenile Myoclonic Epilepsy

被引:0
|
作者
Jara-Prado, Aurelio [1 ]
Guerrero-Camacho, Jorge Luis [1 ]
Angeles-Lopez, Quetzalli Denisse [2 ]
Ochoa-Morales, Adriana [1 ]
de Montellano, David Jose Davila-Ortiz [1 ]
Ramirez-Garcia, Miguel Angel [1 ]
Breda-Yepes, Michelle [3 ]
Duron, Reyna M. [4 ]
Delgado-Escueta, Antonio V. [5 ]
Barrios-Gonzalez, Diego A. [3 ]
Martinez-Juarez, Iris E. [3 ]
机构
[1] Natl Inst Neurol & Neurosurg, Genet Dept, Mexico City, Mexico
[2] UNAM, Fac Estudios Super Cuautitlan, Cuautitlan, Mexico
[3] Natl Inst Neurol & Neurosurg, Epilepsy Clin, Mexico City, Mexico
[4] Univ Tecnol Ctr Amer UNITEC, Tegucigalpa, Honduras
[5] UCLA, Dept Neurol, David Geffen Sch Med, Los Angeles, CA USA
关键词
Juvenile Myoclonic Epilepsy; Risk Factor; Genetic Variants; ABCB1; CYPC219; genes; Genes Interaction; BLOOD-BRAIN-BARRIER; BINDING CASSETTE TRANSPORTERS; MDR1; GENE; ULCERATIVE-COLITIS; CYTOCHROMES P450; DRUG-RESISTANCE; P-GLYCOPROTEIN; POLYMORPHISMS; HAPLOTYPES; C3435T;
D O I
10.1007/s10072-023-07124-w
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Juvenile myoclonic epilepsy (JME) is the most common of the generalized genetic epilepsies, with multiple causal and susceptibility genes; however, its etiopathogenesis is mainly unknown. The toxic effects caused by xenobiotics in cells occur during their metabolic transformation, mainly by enzymes belonging to cytochrome P450. The elimination of these compounds by transporters of the ABC type protects the central nervous system, but their accumulation causes neuronal damage, resulting in neurological diseases. The present study has sought the association between single nucleotide genetic variants of the CYP2C9, CYP2C19, and ABCB1 genes and the development of JME in patients compared to healthy controls. The CC1236 and GG2677 genotypes of ABCB1 in women; allele G 2677, genotypes GG 2677 and CC 3435 in men; the CYP2C19*2A allele, and the CYP2C19*3G/A genotype in both sexes were found to be risk factors for JME. Furthermore, carriers of the TTGGCC genotype combination of the ABCB1 gene (1236/2677/3435) have a 10.5 times higher risk of developing JME than non-carriers. Using the STRING database, we found an interaction between the proteins encoded by these genes and other possible proteins. These findings indicate that the CYP450 system and ABC transporters could interact with other genes in the JME.
引用
收藏
页码:1635 / 1643
页数:9
相关论文
共 50 条
  • [21] Lipophilicity relationships in inhibitors of CYP2C9 and CYP2C19 enzymes
    Lewis, David F. V.
    Lake, Brian G.
    Ito, Yuko
    Dickins, Maurice
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2006, 21 (04) : 385 - 389
  • [22] Developmental expression of human hepatic CYP2C9 and CYP2C19
    Koukouritaki, SB
    Manro, JR
    Marsh, SA
    Stevens, JC
    Rettie, AE
    McCarver, DG
    Hines, RN
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (03): : 965 - 974
  • [23] Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis
    Ercan, B.
    Ayaz, L.
    Cicek, D.
    Tamer, L.
    CELL BIOCHEMISTRY AND FUNCTION, 2008, 26 (03) : 309 - 313
  • [24] INTERINDIVIDUAL DIFFERENCES IN PHENYTOIN ORAL BIOAVAILABILITY: INFLUENCE OF VARIANTS IN ABCB1 AND CYP2C9
    Kijsanayotin, P.
    Cloyd, J.
    Brundage, R.
    Oetting, W.
    Birnbaum, A.
    Ramsay, E.
    Rarick, J.
    White, J.
    Leppik, I.
    EPILEPSIA, 2009, 50 : 213 - 213
  • [25] Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants
    Hiratsuka, Masahiro
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (11) : 1748 - 1759
  • [26] Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy
    Lakhan, Ram
    Kumari, Ritu
    Singh, Kavita
    Kalita, Jayanti
    Misra, Usha Kant
    Mittal, Balraj
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2011, 134 (03) : 295 - 301
  • [27] Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations
    Sychev, Dmitrij Alekseevitch
    Shuev, Grigorij Nikolaevich
    Suleymanov, Salavat Shejhovich
    Ryzhikova, Kristina Anatol'evna
    Mirzaev, Karin Badavievich
    Grishina, Elena Anatol'evna
    Snalina, Natalia Evgenievna
    Sozaeva, Zhannet Alimovna
    Grabuzdov, Anton Mikhailovich
    Matsneva, Irina Andreevna
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2017, 10 : 93 - 99
  • [28] Research of CYP2C9 and CYP2C19 gene polymorphism in evaluation of treatment effectiveness in children with epilepsy
    Guzeva, V. I.
    Guzeva, V.
    Guzeva, O.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 430 - 430
  • [29] Human recombinant polymorphic variants of CYP2C9 and CYP2C19 and its application to pharmacogenetic studies
    Haidukevich, I. V.
    Sushko, T. A.
    Iosko, A. M.
    Veremeichik, A. O.
    Gilep, A. A.
    Usanov, S. A.
    FEBS JOURNAL, 2013, 280 : 334 - 335
  • [30] Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
    Kudzi, William
    Dodoo, Alexander N. O.
    Mills, Jeremy J.
    BMC MEDICAL GENETICS, 2009, 10